Ligelizumab (QGE031)

ligelizumab · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ligelizumab (QGE031), covering 2024-06-18 to 2024-06-18. Get the full timeline:

Most recent: Clinical Trial Update: Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria [Phase 1]